2019 proved to be a pivotal year for the skin microbiome, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ .. Read more skincare products. Clearly, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations. Moving forward into 2021, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis, to truly personalized skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products. Six new topics to explore: The skin-gut axis and the development of ingestible beauty products. Next generation sequencing techniques and their application in claims development. He collaborates extensively with scientists in academia and the biotechnology industry and is a member of several academic/governmental/industrial organizations, including the Association of Biomedical Resource Facilities Microarray Research Group (ABRF-MARG), the Association of Molecular Pathology (AMP), and the Society for Investigative Dermatology (SID); as well as the Scientific Advisory Board of NuGEN Technologies, Inc. Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics.
- [ Users who have shown interest for this Event ]
- Share your Experience